DEF: N2OFF Seeks Shareholder Nod for MitoCareX Buy, Reverse Split

N2OFF, Inc. calls a special meeting to approve the acquisition of cancer drug discovery firm MitoCareX Bio Ltd., a significant stock issuance, and a reverse stock split to maintain Nasdaq listing.

Summary

• N2OFF, Inc. is seeking stockholder approval for four key proposals at a Special Meeting on September 25, 2025.
• The primary proposal is the acquisition of MitoCareX Bio Ltd., an Israeli private company focused on cancer drug discovery targeting mitochondrial proteins, particularly for Non-Small Cell Lung Cancer (NSCLC).
• As consideration for the acquisition, N2OFF will issue approximately 40% of its outstanding Common Stock on a fully-diluted basis to MitoCareX's sellers (Dr. Alon Silberman, Prof. Ciro Leonardo Pierri, and SciSparc Ltd.), plus a $700,000 cash payment to SciSparc.
• Additional contingent consideration includes up to 25% of N2OFF's fully-diluted stock if MitoCareX achieves certain milestones by December 31, 2028, and 30% of gross proceeds from N2OFF's future financing transactions (capped at $1.6 million) within five years post-closing.
• N2OFF has committed an initial investment of $1 million to MitoCareX for R&D, with $750,000 already provided via prior loans.
• A reverse stock split proposal, with a ratio between 1-for-2 and 1-for-150, is also on the agenda, primarily to increase N2OFF's per-share trading price to meet Nasdaq's $1.00 minimum bid price requirement and avoid delisting.
• Stockholders will also vote on the issuance of 1,850,000 shares of Common Stock upon exercise of a warrant issued to L.I.A. Pure Capital Ltd., which is subject to anti-dilution provisions.
• The Board unanimously recommends voting FOR all proposals.

Sentiment

Score: 3

Explanation: The filing presents a highly speculative and high-risk scenario. While the acquisition of a biotech company with a focus on cancer drug discovery offers potential long-term upside, the target (MitoCareX) is in a very early, unproven stage with no revenue and significant losses, requiring substantial future funding. The immediate and extensive dilution for existing shareholders, coupled with N2OFF's own Nasdaq compliance issues and the negative development regarding MitoCareX's patent applications, indicates significant near-term challenges and uncertainties. The necessity of a reverse stock split to maintain listing further underscores the precarious financial position.

Positives

• Acquisition of MitoCareX Bio Ltd. adds a cancer drug discovery pipeline, specifically targeting Non-Small Cell Lung Cancer (NSCLC), which is a significant global market.
• MitoCareX possesses proprietary technology, including the MITOLINE algorithm for 3D protein modeling and advanced computational chemistry platforms, which could enhance N2OFF's technological portfolio.
• The acquisition is expected to bring technological and operational synergies and strengthen the combined management team.
• MitoCareX's research focuses on overcoming drug resistance in NSCLC, addressing a critical unmet medical need.
• The MITOLINE algorithm has potential for commercialization through licensing and strategic partnerships, offering future revenue streams via upfront payments, milestones, and royalties.
• N2OFF has committed an initial $1,000,000 investment to MitoCareX for ongoing research and development, demonstrating support for the acquired entity.

Negatives

• Current N2OFF stockholders will experience significant immediate dilution, with approximately 40% of outstanding Common Stock (fully-diluted basis) being issued to MitoCareX sellers at closing.
• Further potential dilution of up to 25% of N2OFF's fully-diluted capital stock could occur if MitoCareX achieves certain milestones, and an additional 5% in Restricted Stock Units will be granted to MitoCareX's CEO.
• MitoCareX Bio Ltd. has no operating history, no products approved for commercial sale, and has not generated any revenue from product sales since its inception in February 2022.
• MitoCareX has incurred significant operating losses, with a net loss of $307,000 for the three months ended March 31, 2025, and $886,000 for the year ended December 31, 2024, resulting in an accumulated deficit of $2,067,000 as of March 31, 2025.
• MitoCareX's existing cash and cash equivalents are projected to be sufficient only until September-October 2025, indicating an urgent need for substantial additional capital.
• MitoCareX's scientific approach to drug discovery is unproven, with only one Anti-Cancer Small Molecule Therapeutic (ACSMT) in early preclinical/discovery development.
• MitoCareX withdrew two provisional patent applications in February 2025 related to its hit compound 1 because latest scientific results did not support prosecuting them, indicating a setback in intellectual property protection.
• N2OFF's stock price has significantly declined from $0.433 on February 24, 2025, to $0.23 on August 4, 2025.
• N2OFF received a Nasdaq deficiency letter on March 28, 2025, for failing to meet the $1.00 minimum bid price requirement, with a compliance deadline of September 4, 2025.
• A prior 1-for-7 reverse stock split effected on October 5, 2023, may limit N2OFF's eligibility for future compliance periods under Nasdaq Listing Rule 5810(c)(3)(A)(iv) if another reverse split is needed before October 5, 2025.
• The contingent cash consideration to sellers from future N2OFF financing transactions (up to $1.6 million) could reduce the net proceeds retained from such capital raises.

Risks

• The acquisition may not be consummated if conditions, such as stockholder approval or obtaining a ruling from the Israel Tax Authority, are not satisfied or waived.
• The market price of N2OFF's Common Stock may decline significantly due to the substantial dilution from the issuance of approximately 40% of outstanding shares at closing, potential additional 25% for milestones, and 5% in restricted stock units to MitoCareX's CEO.
• The value of N2OFF shares issued in the acquisition may be more or less than the fair market value of MitoCareX's share capital, as MitoCareX is a private company with no public market for its shares.
• Integration of MitoCareX may result in significant accounting charges, including cash expenses, non-cash restructuring charges, and amortization of intangible assets, which could adversely affect N2OFF's financial results.
• Unexpected consequences from undiscovered risks in MitoCareX's business during the due diligence process could lead to unexpected financial liabilities for N2OFF.
• MitoCareX may face difficulties recruiting and retaining additional qualified employees and consultants needed for expansion, potentially disrupting operations and diverting N2OFF management's attention.
• MitoCareX has no operating history, no approved products, and has incurred significant operating losses since inception, with its scientific approach to drug discovery being unproven.
• MitoCareX's existing capital is insufficient to complete the development of its Anti-Cancer Small Molecule Therapeutics (ACSMT), and it will require substantial additional funding beyond September-October 2025.
• Failure to obtain necessary capital on acceptable terms could force MitoCareX to delay, limit, reduce, or terminate its research and development programs, commercialization efforts, or even cease operations.
• Raising additional capital through equity or convertible debt financings may cause further dilution to N2OFF's stockholders or involve restrictive covenants.
• Future collaborations or licensing arrangements to raise funds may require N2OFF to relinquish valuable rights to future revenue streams, intellectual property, or proprietary technology.
• The development of ACSMT is a time-consuming, expensive, and uncertain process, and MitoCareX may never generate the necessary data or results for regulatory approval and commercialization.
• Intellectual property protection in the biopharmaceutical industry is uncertain, with risks of blocking patents, challenges to N2OFF's patents, independent development by competitors, and patent expiration before commercialization.
• Reliance on trade secret protection carries risks of unauthorized disclosure or independent development by third parties.
• Securities litigation or shareholder derivative litigation may arise in connection with the acquisition, diverting management's attention and resources.
• The proposed reverse stock split may not increase N2OFF's stock price over the long term or proportionally, and could decrease liquidity.
• N2OFF's prior reverse stock split on October 5, 2023 (1-for-7) may impact its eligibility for future Nasdaq compliance periods under Rule 5810(c)(3)(A)(iv), potentially leading to delisting if the minimum bid price requirement is not met.
• Failure to approve the reverse stock split could result in the delisting of N2OFF's Common Stock from Nasdaq, adversely affecting liquidity, trading volume, and the ability to raise capital.
• If the Warrant Shares Proposal is not approved, N2OFF may incur significant compensation obligations to the warrant holder (L.I.A. Pure Capital Ltd.) and could be required to buy back the warrant for its Black Scholes Value in cash.

Future Outlook

N2OFF expects to strengthen its competitive position in the biotechnology market and generate long-term potential for increased shareholder value through the acquisition of MitoCareX. MitoCareX anticipates continued and substantially increasing losses as it advances its Anti-Cancer Small Molecule Therapeutics (ACSMT) through preclinical studies and clinical trials, seeks regulatory approval, and potentially commercializes products. MitoCareX's existing cash is projected to fund operations only until September-October 2025, necessitating substantial additional funding. N2OFF has committed to providing an initial $1 million investment to MitoCareX and will make further funding available for ongoing R&D if its board approves an operating plan and N2OFF possesses the financial resources. MitoCareX aims to clinically test its final lead product initially for previously treated advanced NSCLC patients and is exploring combination therapies to overcome drug resistance.

Management Comments

• "You are cordially invited to attend the special meeting of stockholders of N2OFF, Inc."
• "Your vote is very important regardless of the number of shares of our voting securities that you own. I encourage you to vote by telephone, over the Internet, or by marking, signing, dating and returning your proxy card so that your shares will be represented and voted at the Special Meeting, whether or not you plan to attend."
• "On behalf of our Board, I urge you to submit your proxy as soon as possible, even if you currently plan to attend the Special Meeting in person."
• "After careful consideration, THE BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE FOR the Acquisition Proposal (Proposal 1); FOR the Reverse Stock Split Proposal (Proposal 2), FOR the Warrant Shares Proposal (Proposal 3) and FOR the Adjournment Proposal (Proposal 4) if presented."
• "Management believes that the acquisition of MitoCareX is consistent with the Company’s strategic objective to identify and invest in innovative technologies and high-potential sectors."
• "The Company believes that acquiring MitoCareX will enable it to: Access a promising research and development pipeline and proprietary intellectual property; Strengthen its competitive position in the biotechnology market; Generate long-term potential for increased shareholder value."

Industry Context

The acquisition of MitoCareX Bio Ltd. by N2OFF, Inc. reflects a broader trend in the biotechnology and pharmaceutical industries towards strategic consolidation and the pursuit of innovative drug discovery platforms, particularly in high-growth areas like oncology. MitoCareX's focus on mitochondrial carrier proteins and its use of computational chemistry (MITOLINE algorithm) aligns with the increasing integration of AI and structural biology in drug design, aiming to accelerate the identification of novel drug targets and candidates. The global market for mitochondria-based therapies is projected for significant growth, and the lung cancer treatment market, especially for NSCLC, is undergoing rapid transformation with a pressing need for new treatments to overcome drug resistance. This acquisition positions N2OFF to potentially capitalize on these trends, although MitoCareX's early-stage development and unproven scientific approach highlight the inherent high-risk, high-reward nature typical of early-stage biopharma investments.

Comparison to Industry Standards

• MitoCareX's focus on the SLC25A protein family as a drug target is considered unique, as there are currently no FDA-approved drugs specifically targeting this family, indicating a novel approach compared to established therapies.
• The company's use of a proprietary algorithm (MITOLINE) for 3D protein modeling and virtual screening is consistent with advanced computational drug discovery engines employed by competitors like Relay Therapeutics (Dynamo platform), which also integrate dynamic protein motion with AI-driven design.
• MitoCareX's aim to overcome drug resistance in NSCLC, particularly for EGFR inhibitors and platinum-based chemotherapies, addresses a critical challenge in the lung cancer treatment landscape, similar to efforts by companies developing fourth-generation EGFR inhibitors like Scorpion Therapeutics (STX-241) or antibody-drug conjugates like Daiichi Sankyo (Patritumab deruxtecan).
• However, unlike these competitors which have products in IND-enabling studies or Phase 2 trials, MitoCareX's sole Anti-Cancer Small Molecule Therapeutic (ACSMT) is still in the preclinical/discovery stage, indicating a significantly earlier development phase compared to industry benchmarks for companies seeking to address similar unmet needs.
• MitoCareX's lack of operating history, revenue, and significant accumulated losses are typical for early-stage biotech startups but contrast sharply with more mature biopharmaceutical companies that have established pipelines and commercialized products.

Management Changes

Corporate Governance

Legal Proceedings

• No current legal proceedings are explicitly stated as pending against N2OFF or MitoCareX.
• The filing notes a risk of securities litigation or shareholder derivative litigation frequently following the announcement of significant business transactions like the acquisition.

Related Party Transactions

• Two N2OFF board members, Amitay Weiss (Chairman) and Liat Sidi, also serve as board members of SciSparc Ltd., one of the sellers in the MitoCareX acquisition.
• Dr. Alon Silberman, a co-founder, Chief Scientific Officer, and board member of MitoCareX (and a seller), is the brother of Kfir Silberman, the owner of L.I.A. Pure Capital Ltd., which is a stockholder and lender to N2OFF.
• SciSparc Ltd. is a seller of MitoCareX shares to N2OFF, receiving a cash payment of $700,000 and N2OFF Common Stock.
• L.I.A. Pure Capital Ltd. is the recipient of a warrant to purchase 1,850,000 shares of N2OFF Common Stock and has provided loans to MitoCareX (e.g., $250,000 on December 22, 2024, and $250,000 on March 12, 2025) which will be deducted from N2OFF's initial investment in MitoCareX.

Stakeholder Impact

• Shareholders (N2OFF): Will experience significant immediate and potential future dilution of their ownership percentage due to the issuance of new shares for the acquisition and contingent milestones. Face risks of stock price decline and potential delisting if the reverse stock split fails to maintain Nasdaq compliance.
• Employees (MitoCareX): The CEO, Dr. Alon Silberman, will continue his employment with MitoCareX under an amended agreement, receiving restricted stock units in N2OFF. The company may expand its organization, potentially creating new opportunities.
• L.I.A. Pure Capital Ltd.: As a warrant holder and lender, its interests are tied to the approval of the warrant shares issuance and the financial health of N2OFF, with provisions for compensation if warrant shares are not issued.
• Sellers (SciSparc, Dr. Alon Silberman, Prof. Ciro Leonardo Pierri): Will become significant shareholders of N2OFF and are eligible for additional shares based on milestones and a percentage of future N2OFF financing proceeds, aligning their interests with the combined entity's success.
• Creditors: The acquisition and future financing plans could impact N2OFF's debt structure and ability to meet obligations.

Next Steps

• Special Meeting of Stockholders to be held on September 25, 2025, to vote on the acquisition, reverse stock split, warrant shares issuance, and meeting adjournment.
• If approved, N2OFF will proceed with the acquisition of MitoCareX Bio Ltd., making it a wholly-owned subsidiary.
• If approved, N2OFF's board of directors may effect a reverse stock split within one year after stockholder approval.
• If approved, N2OFF will issue 1,850,000 shares of Common Stock upon exercise of the warrant to L.I.A. Pure Capital Ltd.
• N2OFF expects to publish voting results in a Current Report on Form 8-K within four business days following the Special Meeting.
• MitoCareX will continue its preclinical studies and clinical trials for its Anti-Cancer Small Molecule Therapeutics (ACSMT) and further develop its MITOLINE algorithm.
• MitoCareX plans to file additional patent applications as appropriate to support its intellectual property strategy.
• N2OFF will provide an initial $1,000,000 investment to MitoCareX upon closing, and further funding for ongoing R&D subject to board approval and financial resources.
• MitoCareX aims to test its developed compounds in a dedicated preclinical setting and eventually clinically test its lead product for previously treated advanced NSCLC patients.

Key Dates

Recommendation

The filing outlines a highly speculative and complex transaction. While the acquisition of MitoCareX offers N2OFF a strategic entry into cancer drug discovery with proprietary technology, MitoCareX is an early-stage, pre-revenue company with significant losses and immediate funding needs. This introduces substantial financial risk and will lead to significant dilution for existing N2OFF shareholders. The proposed reverse stock split is a necessary defensive measure to maintain Nasdaq listing, but its long-term effectiveness is uncertain, and prior corporate actions limit future flexibility. The withdrawal of MitoCareX's patent applications is a notable negative. Given the high level of uncertainty, the substantial dilution, and the unproven nature of the acquired assets, a "hold" recommendation is appropriate. Existing investors should monitor the execution of the acquisition, the progress of MitoCareX's pipeline, and N2OFF's ability to secure future funding and maintain Nasdaq compliance. New investment at this stage is highly speculative.

Keywords

N2OFF, MitoCareX, Acquisition, Reverse Stock Split, Nasdaq Listing, Biotechnology, Cancer Therapeutics, NSCLC, Drug Discovery, MITOLINE, Dilution, SEC Filing, Proxy Statement, Corporate Governance, Warrant Issuance, Financial Reporting, Risk Management, Strategic Analysis, Biopharma, Oncology